Iberdomide is an experimental thalidomide analog[1] that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide.

It is developed by Bristol Myers Squibb for various cancers[2][3][4][5][6][7][8] and was also tested in people with lupus.

[9]